1. Rabe E., Guex J.J., Puskas A. et al. Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. PMID: 22466974.
2. Seliverstov E.I., Avak’yants I.P., Nikishkov A.S., Zolotukhin I.A. Epidemiology of Chronic Venous Disease. Flebologiya. 2016;10(1):35–43 (in Russ.). DOI: 10.17116/flebo201610135-42.
3. Kirienko A.I., Bogachev V.Y., Gavrilov S.G. et al. Chronic diseases of lower limb veins in Moscow industrial enterprises employees (results of epidemiological study). Angiologia i sosudistaya khirurgia. 2004;10(1):77–86 (in Russ.).
4. Zolotukhin I.A., Seliverstov E.I., Shevtsov Yu.N. et al. Prevalence of Chronic Venous Disease: Results of Population Based Epidemiological Study. Flebologiya. 2016;10(3):119–125 (in Russ.). DOI: 10.17116/flebo2016103119-125.
5. Matic P., Jolic S., Tanaskovic S. et al. Chronic Venous Disease and Comorbidities. Angiology. 2015;66(6):539–544. DOI: 10.1177/0003319714541988.
6. Rabe E., Régnier C., Goron F. et al. The prevalence, disease characteristics and treatment of chronic venous disease: an international web-based survey. J Comp Eff Res. 2020;9(17):1205–1218. DOI: 10.2217/cer-2020-0158.
7. Baev V.M., Vagapov T.F., Shmeleva S.A. Comorbidity of hypertension and chronic venous disease in men. Rossiyskiy kardiologicheskiy zhurnal. 2020;25(3):3258 (in Russ.). DOI: 10.15829/1560-4071-2020-3-3258.
8. Sinyachenko O.V., Ermolaeva M.V., Pilipenko R.V. et al. Varicose vein disease and comorbid diabetes mellitus. Report 1: Changes in carbohydrate metabolic parameters in blood from elbow and affected veins of the lower extremities. Mezhdunarodniy endokrinologicheskiy zhurnal. 2019;15(7):535–540 (in Russ.). DOI: 10.22141/2224-0721.15.7.2019.186056.
9. Baracchini C., Perini P., Calabrese M. et al. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol. 2011;69(1):90–99. DOI: 10.1002/ana.22228.
10. Canhao P., Falcao F., Ferro J.M. Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis. 2003;15(3):159–166. DOI: 10.1159/000068833.
11. Sun H.J., Wu Z.Y., Nie X.W., Bian J.S. Role of Endothelial Dysfunction in Cardiovascular Diseases: The Link Between Inflammation and Hydrogen Sulfide. Front Pharmacol. 2020;10:1568. DOI: 10.3389/fphar.2019.01568.
12. Castro-Ferreira R., Cardoso R., Leite-Moreira A., Mansilha A. The Role of Endothelial Dysfunction and Inflammation in Chronic Venous Disease. Ann Vasc Surg. 2018;46:380–393. DOI: 10.1016/j.avsg.2017.06.131.
13. Barthelmes J., Nägele M.P., Ludovici V. et al. Endothelial dysfunction in cardiovascular disease and Flammer syndrome-similarities and differences. EPMA J. 2017;8(2):99–109. DOI: 10.1007/s13167-017-0099-1.
14. Favero G., Paganelli C., Buffoli B. et al. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int. 2014;2014:801896. DOI: 10.1155/2014/801896.
15. Levy J.H., Iba T., Gardiner E.E. Endothelial Injury in COVID-19 and Acute Infections: Putting the Pieces of the Puzzle Together. Arterioscler Thromb Vasc Biol. 2021;41(5):1774–1776. DOI: 10.1161/ATVBAHA.121.316101.
16. Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. DOI: 10.1016/S0140-6736(20)30937-5.
17. Gustafson D., Raju S., Wu R. et al. Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis? Arterioscler Thromb Vasc Biol. 2020;40(8):1818–1829. DOI: 10.1161/ATVBAHA.120.314558.
18. Bombardelli Е., Morazzoni P., Griffini A. Aesculus hippocastanum L. Fitoterapia. 1996;67(6):483–511. DOI:10.1201/b10413-17.
19. Zurabyan S.E. Nomenclature of natural compounds: a reference guide. M.: GEOTAR-Media; 2008 (in Russ.).
20. Frick R.W. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology. 2000;51(3):197–205. DOI: 10.1177/000331970005100303.
21. Arnould T., Janssens D., Michiels C., Remacle J. Effect of aescine on hypoxia-induced activation of human endothelial cells. Eur J Pharmacol. 1996;315(2):227–233. DOI: 10.1016/s0014-2999(96)00645-0.
22. Sirtori C.R. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183–193. DOI: 10.1006/phrs.2001.0847.
23. Ezberci F., Ünal E. Aesculus Hippocastanum (Aescin, Horse Chestnut) in the Management of Hemorrhoidal Disease: Review. Turk J Colorectal Dis. 2018;28(2):54–57. DOI: 10.4274/tjcd.16442.
24. Muravyova D.A., Samylina I.A., Yakovlev G.P. Pharmacognosy: textbook. M.: Medicine; 2002 (in Russ.).
25. Francischetti I.M., Monteiro R.Q., Guimarães J.A. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Commun. 1997;235(1):259–263. DOI: 10.1006/bbrc.1997.6735.
26. Nakata N., Kira Y., Yabunaka Y., Takaoka K. Prevention of venous thrombosis by preoperative glycyrrhizin infusion in a rat model. J Orthop Sci. 2008;13(5):456–462. DOI: 10.1007/s00776-008-1259-x.
27. Fuhrman B., Volkova N., Kaplan M. et al. Antiatherosclerotic effects of licorice extract supplementation on hypercholesterolemic patients: increased resistance of LDL to atherogenic modifications, reduced plasma lipid levels, and decreased systolic blood pressure. Nutrition. 2002;18(3):268–273. DOI: 10.1016/s0899-9007(01)00753-5.
28. Majnskov A.V., Kiseleva T.L., Kolhir V.K. et al. Herbal medicines in the treatment of chronic venous insufficiency. M.: MOKB Mars; 1999 (in Russ.).
29. Sokolov S.J., Zamotaev I.P. Medicinal Plants: A Handbook. M.; Meditsina; 1988 (in Russ.).
30. Venskutonis P.R. Phytochemical composition and bioactivities of hawthorn (Crataegus spp.): review of recent research advances. Journal of Food Bioactives. 2018;4:69–87. DOI: 10.31665/JFB.2018.4163.
31. May J.M., Harrison F.E. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal. 2013;19(17):2068–2083. DOI: 10.1089/ars.2013.5205.
32. Ashor A.W., Siervo M., Lara J. et al. Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr. 2015;113(8):1182–1194. DOI: 10.1017/S0007114515000227.
33. Nađpal J.D., Lesjak M.M., Šibul F.S. et al. Comparative study of biological activities and phytochemical composition of two rose hips and their preserves: Rosa canina L. and Rosa arvensis Huds. Food Chem. 2016;192:907–914. DOI: 10.1016/j.foodchem.2015.07.089.
34. Kolkhir V.K., Voskoboynikova I.V. Composition "Angionorm”, which has anti-aggregation, capillary-protective, venotonic action. RF patent for invention RU2241483C1. Published 10.12.2004.
35. Korsun V.F., Kolhir V.K., Voskoboynikova I.V. et al. The use of angionorm after mastectomy: Guidelines. M.: RUDN; 2009 (in Russ.).
36. Korsun E.V. Report on clinical and laboratory study of the effectiveness of the domestic drug Angionorm in hemorrhoids. "Institute of phytotherapy”. M.; 2013 (in Russ.).
37. Voskoboynikova I.V., Korsun V.F., Kolhir V.K., Korsun E.V. Angionorm in the treatment of hemorrhoids. In: Collection of abstracts of the XXI Russian National Congress "Man and Medicine”. M.; 2014:29–30 (in Russ.).
38. Chuiko T.V., Korsun V.F., Voskoboynikova I.V. et al. AngioNorm® after myocardial infarction. Medicinskiy alfavit. 2016;1(8):40–44 (in Russ.).
39. Voskoboynikova I.V., Korsun V.F., Kolhir V.K., Korsun E.V. AngioNorm in postinfarction cardiosclerosis. In: Collection of abstracts of the XXI Russian National Congress "Man and Medicine”. M.; 2014:29 (in Russ.).
40. Garganeeva N.P., Barbarash O.L., Altarev S.S. et al. Antithrombotic efficacy of a domestic herbal medicine in the complex therapy of unstable angina pectoris. Lechashchij vrach. 2013;2:126–128 (in Russ.).
41. Chapaeva N.N. Angionorm in therapy of patients with chronic venous insufficiency and other vascular disorders. (Electronic resource.) URL: https://medi.ru/info/2733/ (access date: 03.03.2022) (in Russ.).